Skip to main content
EXAGEN INC. logo

EXAGEN INC. — Investor Relations & Filings

Ticker · XGN ISIN · US30068X1037 LEI · 549300JV2CYDOME5OO17 US Human health and social work activities
Open in API
Filings indexed 397 across all filing types
Latest filing 2026-05-12 Share Issue/Capital Cha…
Country US United States of America
Listing US XGN

About EXAGEN INC.

https://exagen.com/

Exagen Inc. is a commercial-stage life sciences company focused on transforming the care continuum for patients with complex autoimmune diseases. Operating as a rheumatology specialty laboratory, the company develops and provides advanced testing solutions for the diagnosis, prognosis, and monitoring of these conditions. Its core offering is the AVISE® testing portfolio, which leverages proprietary biomarker technology to provide physicians with critical insights for timely and accurate differential diagnosis. These tools are designed to empower healthcare providers, particularly rheumatologists, in managing debilitating chronic diseases such as lupus and rheumatoid arthritis, ultimately aiming to improve patient outcomes.

Recent filings

Filing Released Lang Actions
S-8 - EXAGEN INC. (0001274737) (Filer)
Share Issue/Capital Change Classification · 85% confidence The document is a Securities and Exchange Commission registration statement on Form S-8, used to register new shares under the company’s employee stock plans. It is not an annual or quarterly report, earnings release, or management discussion, but rather a filing to authorize and register share issuances under employee benefit plans. This falls under the category of announcements regarding new share issues or capital changes.
2026-05-12 English
10-Q - EXAGEN INC. (0001274737) (Filer)
Interim / Quarterly Report Q1 2026
2026-05-11 English
8-K - EXAGEN INC. (0001274737) (Filer)
Earnings Release Classification · 95% confidence The document is an SEC Form 8-K Current Report whose primary substance is the Company’s press release reporting quarterly financial results for the period ended March 31, 2026 (Item 2.02 Results of Operations and Financial Condition). This constitutes the initial announcement of periodical financial results (key highlights only) rather than the full financial report. Therefore, it should be classified as an Earnings Release (ER). Q1 2026
2026-05-11 English
ARS - EXAGEN INC. (0001274737) (Filer)
Annual Report FY 2025
2026-04-27 English
DEF 14A - EXAGEN INC. (0001274737) (Filer)
Proxy Solicitation & Information Statement
2026-04-27 English
8-K - EXAGEN INC. (0001274737) (Filer)
Board/Management Information Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated April 17, 2026. The key content is the resignation of a board member and the resulting changes in the board committees. There are no financial statements or detailed financial data presented. The primary focus is on management/board changes, specifically the departure of a director and committee reassignments. According to the filing definitions, announcements of changes in the company's board of directors or senior management fall under Board/Management Information (MANG). The document length is 3860 characters, which is relatively short and consistent with a typical 8-K filing for management changes. Therefore, the appropriate classification is MANG with high confidence.
2026-04-23 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.